Study guide

7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules

Key Takeaways Explain This Topic AI

Primary hypothyroidism is characterized by an elevated serum TSH and low Free T4; Hashimoto's (autoimmune) thyroiditis is the leading etiology in iodine-sufficient regions, confirmed by elevated anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) antibodies.

Levothyroxine (L-thyroxine) is dosed at ~1.6 mcg/kg/day ideal body weight in young, healthy adults, but older adults and patients with known coronary artery disease must start low ('start low and go slow': 12.5–25 mcg/day) to prevent precipitating angina, myocardial ischemia, or tachyarrhythmias.

Hyperthyroidism etiology is differentiated by 24-hour Radioactive Iodine Uptake (RAIU): diffuse, homogenous high uptake indicates Graves' disease; patchy, heterogeneous uptake indicates Toxic Multinodular Goiter; suppressed/low uptake (<5%) indicates subacute thyroiditis, postpartum thyroiditis, or factitious/exogenous thyrotoxicosis.

Subacute granulomatous (De Quervain's) thyroiditis is a post-viral inflammatory disorder presenting with an exquisitely painful, tender thyroid gland, markedly elevated ESR/CRP, low RAIU, and a triphasic clinical course (hyperthyroid → hypothyroid → euthyroid), treated with NSAIDs or oral prednisone.

Thyroid nodule evaluation begins with serum TSH: a suppressed TSH prompts a radionuclide iodine scan (hot nodules are rarely malignant); a normal or elevated TSH warrants neck ultrasound and risk stratification using ACR TI-RADS criteria to determine fine-needle aspiration (FNA) biopsy thresholds.

Last updated: August 2026

Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules

Thyroid disorders represent some of the most prevalent endocrine pathologies encountered in adult-gerontology primary care practice. Thyroid hormones (thyroxine [ T 4 T_4 T 4 ​ ] and triiodothyronine [ T 3 T_3 T 3 ​ ]) act on virtually every cell in the human body to regulate basal metabolic rate, cardiac inotropy/chronotropy, protein synthesis, lipid turnover, and neuromuscular excitability. Derangements in thyroid homeostatic circuitry manifest as subtle, insidious clinical syndromes in older adults or fulminant, life-threatening metabolic crises (myxedema coma and thyroid storm).

For the AGPCNP, board certification requires mastery of the hypothalamic-pituitary-thyroid (HPT) axis feedback loop, pharmacological nuances of replacement and suppression therapies, radioactive iodine uptake scan interpretation, thyroiditis differentiation, and evidence-based workups for thyroid nodules and malignancies.

1. The Hypothalamic-Pituitary-Thyroid (HPT) Axis & Diagnostic Serology +---------------------------------------------------------------------------------------------------+

  • | HYPOTHALAMIC-PITUITARY-THYROID (HPT) AXIS |
  • | |
  • | [HYPOTHALAMUS] |
  • | | |
  • | v (TRH: Thyrotropin-Releasing Hormone) |
  • | [ANTERIOR PITUITARY] |
  • | | |
  • | v (TSH: Thyroid-Stimulating Hormone) |
  • | [THYROID GLAND] |
  • | | |
  • | +--------------+--------------+ |
  • | | | |
  • | v v |
  • | [THYROXINE (T4)] [TRIIODOTHYRONINE (T3)] |
  • | (~80-90% output) (~10-20% direct output) |
  • | | | |
  • | +--------------+--------------+ |
  • | | |
  • | v |
  • | [PERIPHERAL 5'-DEIODINATION IN TISSUES] |
  • | (T4 converted to biologically active T3) |
  • | | |
  • | +------------------------------------+ |
  • | | |
  • | [NEGATIVE FEEDBACK] | |
  • | - Elevated Free T4/T3 suppresses TRH and TSH secretion -------------------+ |
  • | - Decreased Free T4/T3 stimulates TRH and TSH secretion |
  • +---------------------------------------------------------------------------------------------------+
  • Diagnostic Serological Patterns in Thyroid Pathology

Diagnostic Pattern Serum TSH Serum Free T4 Serum Free T3 Clinical Etiologies & Diagnostic Pearls

Primary Hypothyroidism Elevated ( ↑ \uparrow ↑ ) Decreased ( ↓ \downarrow ↓ ) Normal or Low Hashimoto's thyroiditis, post-ablative (131-I), surgical thyroidectomy, end-stage severe iodine deficiency.

Subclinical Hypothyroidism Elevated ( ↑ \uparrow ↑ ) Normal ( ↔ \leftrightarrow ↔ ) Normal Early Hashimoto's; recover phase of thyroiditis; check anti-TPO antibodies; treat if TSH > 10 mIU/L >10\text{ mIU/L} > 10 mIU/L or symptomatic.

Secondary / Central Hypothyroidism Low or Inappropriately Normal ( ↓ / ↔ \downarrow / \leftrightarrow ↓ / ↔ ) Decreased ( ↓ \downarrow ↓ ) Low Pituitary macroadenoma, Sheehan syndrome, craniopharyngioma, brain radiation. TSH is uninformative for monitoring!

Primary Hyperthyroidism Suppressed ( < 0.01 <0.01 < 0.01 ) Elevated ( ↑ \uparrow ↑ ) Elevated ( ↑ \uparrow ↑ ) Graves' disease, Toxic Multinodular Goiter, Toxic Solitary Adenoma, early phase thyroiditis.

T3 Toxicosis Suppressed ( < 0.01 <0.01 < 0.01 ) Normal ( ↔ \leftrightarrow ↔ ) Elevated ( ↑ \uparrow ↑ ) Early Graves' disease, autonomous toxic nodule. Always order Free T3 if TSH is suppressed but Free T4 is normal!

Subclinical Hyperthyroidism Suppressed ( < 0.1 <0.1 < 0.1 ) Normal ( ↔ \leftrightarrow ↔ ) Normal ( ↔ \leftrightarrow ↔ ) Exogenous over-replacement, mild multinodular goiter. High risk for AFib and osteoporosis in older adults.

Euthyroid Sick Syndrome Normal / Low / High Normal / Low Decreased ( ↓ \downarrow ↓ ) Non-thyroidal critical illness (ICU, severe sepsis). Deiodinase inhibition; elevated Reverse T3 (rT3) . Do NOT treat with levothyroxine!

  • 2. Hypothyroidism: Pathophysiology, Clinical Manifestations & Levothyroxine Mastery
  • A. Etiologies & Pathophysiology

Hashimoto's Thyroiditis (Chronic Autoimmune Thyroiditis): The most common cause of hypothyroidism in iodine-replete areas. Characterized by cell-mediated lymphocytic infiltration (CD4+ and CD8+ T-cells) and autoantibody-mediated follicular destruction. Serological markers include anti-Thyroid Peroxidase (anti-TPO) antibodies (positive in >95%) and anti-Thyroglobulin (anti-Tg) antibodies (positive in 60–80%).

Iatrogenic / Post-Procedural: Following radioactive iodine (131-I) ablation for Graves' disease, total/subtotal thyroidectomy, or external beam neck radiation.

Drug-Induced Hypothyroidism:

Amiodarone: Contains 37% iodine by molecular weight. Induces hypothyroidism in ~15–20% of patients via the Wolff-Chaikoff effect (high iodine load transiently inhibits thyroid organification) or direct cytotoxic destructive thyroiditis.

Lithium: Inhibits thyroid hormone synthesis and peripheral release (goitrogenic; monitor TSH every 6–12 months).

Immune Checkpoint Inhibitors (PD-1/PD-L1/CTLA-4 Inhibitors): Pembrolizumab, nivolumab, ipilimumab trigger autoimmune hypophysitis or destructive thyroiditis.

B. Multi-System Clinical Presentation

Constitutional & Metabolic: Extreme fatigue, cold intolerance, unexplained modest weight gain (primarily myxedematous fluid retention, rarely >5–10 lbs), hypothermia, slow speech.

Cardiovascular: Sinus bradycardia, narrow pulse pressure, diastolic hypertension (increased systemic vascular resistance), pericardial effusion, elevated LDL-cholesterol (downregulation of hepatic LDL receptors).

Neuromuscular & Neuropsychiatric: "Brain fog", depression, memory loss, proximal muscle weakness, elevated creatine kinase (CK), carpal tunnel syndrome (median nerve compression by mucopolysaccharide deposits), delayed relaxation phase of deep tendon reflexes (Woltman's sign / hung-up reflexes) .

Dermatologic & ENT: Dry, scaly skin ( xerosis ), coarse, brittle, thinning hair, loss of the lateral third of the eyebrows (madarosis / Queen Anne's sign) , non-pitting periorbital and pretibial edema ( myxedema due to hyaluronic acid deposition in the dermis), hoarseness/deepened voice.

Gastrointestinal & Reproductive: Severe constipation, paralytic ileus, menorrhagia (early) or amenorrhea (late), galactorrhea (elevated TRH stimulates anterior pituitary prolactin release). +---------------------------------------------------------------------------------------------------+

  • | LEVOTHYROXINE (L-THYROXINE, T4) DOSING PROTOCOL |
  • | |
  • | [HEALTHY YOUNG ADULT (<50 YRS, NO CAD)] |
  • | - Full Replacement Dose: 1.6 mcg/kg/day (Calculate using Ideal Body Weight, IBW) |
  • | - Example: 70 kg patient -> ~112 mcg daily (prescribe 100-112 mcg/day) |
  • | |
  • | [OLDER ADULT (>=50-65 YRS) OR PATIENT WITH CORONARY ARTERY DISEASE / MULTIMORBIDITY] |
  • | - "START LOW AND GO SLOW": Starting Dose: 12.5 to 25 mcg/day (or 25 to 50 mcg/day) |
  • | - Rationale: Rapid restoration of euthyroidism increases myocardial oxygen demand, precipitating|
  • | acute angina, myocardial infarction, or fatal ventricular arrhythmias. |
  • | - Titration: Increase by 12.5 - 25 mcg increments every 6 to 8 weeks based on serum TSH. |
  • | |
  • | [PREGNANCY] |
  • | - Increase dose by 25 - 30% (e.g., take 2 extra doses per week) immediately upon confirmation |
  • | of pregnancy; TSH goal < 2.5 mIU/L in 1st trimester. |
  • +---------------------------------------------------------------------------------------------------+
  • Levothyroxine Administration & Drug-Nutrient Absorption Interferences

Levothyroxine absorption occurs primarily in the jejunum and ileum, requiring an acidic gastric microenvironment. The AGPCNP must educate every patient on strict administration rules:

Timing: Take immediately upon waking on an empty stomach with a full 8-ounce glass of plain water , at least 30 to 60 minutes before breakfast , or at bedtime at least 3 to 4 hours after the last meal .

Medication Separation (The 4-Hour Rule): The following substances bind levothyroxine in the gut lumen, drastically reducing bioavailability. Separate by a minimum of 4 hours :

Calcium carbonate and calcium citrate supplements.

Ferrous sulfate / iron supplements.

Aluminum-containing antacids, sucralfate, and magnesium hydroxide.

Bile acid sequestrants (cholestyramine, colestipol, colesevelam).

Proton Pump Inhibitors (PPIs) and H2-receptor antagonists (impair acid-dependent dissolution).

Multivitamins containing minerals, soy protein products, and high-fiber supplements.

Monitoring: Recheck serum TSH 6 to 8 weeks after initiating therapy or after any dose modification. Once euthyroid, monitor TSH annually or whenever symptoms change.

C. Myxedema Coma (Decompensated Hypothyroidism)

Pathophysiology & Triggers: Life-threatening medical emergency (mortality 30–50%) resulting from longstanding, severe untreated hypothyroidism complicated by an acute physiological stressor (severe infection, sepsis, myocardial infarction, cold exposure, trauma, or central nervous system depressants).

Hallmark Triad: Hypothermia (temperature frequently < 35 ∘ C [ 95 ∘ F ] <35^\circ\text{C} [95^\circ\text{F}] < 3 5 ∘ C [ 9 5 ∘ F ] ), Altered Mental Status (lethargy, obtundation, myxedema madness, coma), and Cardiorespiratory Depression (bradycardia, severe hypotension, hypoventilation with hypercapnia).

Diagnostic Lab Clues: Hyponatremia (impaired free water clearance / SIADH-like state), hypoglycemia, elevated creatinine kinase, low Free T4/Free T3, highly elevated TSH.

Emergency Treatment Protocol:

IV Glucocorticoids (MANDATORY FIRST STEP): Administer IV Hydrocortisone 100 mg q8h prior to or concurrently with thyroid hormone replacement. (Treating with thyroid hormone alone accelerates cortisol clearance and precipitates fatal adrenal crisis in patients with co-existing autoimmune adrenal insufficiency or central hypopituitarism).

IV Thyroid Hormone Replacement: IV Levothyroxine loading dose (200–400 mcg IV bolus, then 50–100 mcg IV daily) ± \pm ± IV Liothyronine (T3: 5–20 mcg loading dose).

Supportive Care: Passive external rewarming (avoid active warming blankets which cause peripheral vasodilation and vascular collapse), mechanical ventilation for hypercapnic failure, IV 5% Dextrose in normal saline for hypoglycemia/hyponatremia, and broad-spectrum IV antibiotics for occult sepsis.

3. Hyperthyroidism & Thyrotoxicosis: Etiology, RAIU Differentiation & Management +---------------------------------------------------------------------------------------------------+

  • | 24-HOUR RADIOACTIVE IODINE UPTAKE (RAIU) SCAN |
  • | |
  • | [SUPPRESSED TSH + HIGH FREE T4/T3] |
  • | | |
  • | v |
  • | [PERFORM 24-HR RAIU & SCAN] |
  • | | |
  • | +-----------------------------------------+-----------------------------------------+ |
  • | | | |
  • | v v |
  • | [HIGH / NORMAL UPTAKE (>15-30%)] [LOW / SUPPRESSED (<5%)] |
  • | (True De Novo Hyperthyroidism) (Thyroiditis / Exogenous) |
  • | | | |
  • | +-----+-----------------------+-----------------------+ | |
  • | | | | | |
  • | v v v v |
  • | [DIFFUSE HOMOGENEOUS] [MULTIPLE PATCHY HOT] [SINGLE HOT FOCUS] [THYROIDITIS / EXOGENOUS]|
  • | = GRAVES' DISEASE = TOXIC MULTINODULAR = TOXIC ADENOMA - Subacute (De Quervain)|
  • | - Positive TSI / TRAb GOITER (PLUMMER) - Suppressed baseline - Postpartum / Silent |
  • | - Exophthalmos, bruit - Elderly, patchy RAIU parenchyma - Factitious (Low Tg) |
  • | - Pretibial myxedema - Autonomous nodules - Iodine-induced |
  • +---------------------------------------------------------------------------------------------------+
  • A. Graves' Disease (Autoimmune Hyperthyroidism)

Pathophysiology: Autoimmune disorder caused by circulating Thyroid-Stimulating Immunoglobulins (TSI) or TSH-receptor antibodies ( TRAb ) that bind to and chronically activate the follicular TSH receptor, driving autonomous thyroid hormone synthesis, hypertrophy, and hyperplasia.

Extrathyroidal Pathognomonic Manifestations:

Graves' Orbitopathy / Ophthalmopathy (25–50%): Proptosis, periorbital edema, diplopia, chemosis, lid retraction, and optic nerve compression due to T-cell mediated retro-orbital fibroblast activation and glycosaminoglycan accumulation.

Pretibial Myxedema (Thyroid Dermopathy): Non-pitting, violaceous, indurated, "orange-peel" (peau d'orange) plaques over the anterior shins.

Thyroid Acropachy: Digital clubbing and subperiosteal bone formation.

Thyroid Bruit / Thrill: Audible continuous systolic-diastolic vascular murmur over the thyroid lobes reflecting dramatic hypervascularity.

B. Toxic Multinodular Goiter (TMNG / Plummer Disease) & Toxic Adenoma

Autonomous somatic mutations in the TSH receptor gene occurring in longstanding non-toxic multinodular goiters. Most common in older adults (>60 years) .

Manifests without orbitopathy or pretibial myxedema. Patients frequently present with "Apathetic Hyperthyroidism" characterized by depression, lethargy, anorexia, proximal muscle wasting, and new-onset Atrial Fibrillation refractory to standard rate control.

C. Pharmacotherapy & Definitive Management of Hyperthyroidism +---------------------------------------------------------------------------------------------------+

  • | HYPERTHYROIDISM PHARMACOLOGICAL MANAGEMENT |
  • | |
  • | 1. SYMPTOM CONTROL (BETA-BLOCKERS) |
  • | - Propranolol (20-80 mg PO q6-8h) OR Atenolol (25-100 mg daily). |
  • | - Action: Rapidly blunts adrenergic hyperactivity (tachycardia, tremor, palpitations, anxiety); |
  • | High-dose propranolol also inhibits peripheral 5'-deiodinase (blocks T4 to T3 conversion). |
  • | |
  • | 2. THIONAMIDES (ANTITHYROID DRUGS) |
  • | - METHIMAZOLE (MMI, 10-40 mg daily): Preferred first-line agent for almost all non-pregnant |
  • | patients due to once-daily dosing, rapid euthyroid restoration, and lower hepatotoxicity. |
  • | - PROPYLTHIOURACIL (PTU, 100-200 mg TID): Preferred ONLY in: |
  • | * First trimester of pregnancy (MMI is teratogenic: aplasia cutis, choanal atresia). |
  • | * Thyroid Storm (blocks peripheral T4 -> T3 conversion in addition to synthesis). |
  • | * Patients with adverse reactions to MMI where surgery/RAI is not feasible. |
  • | |
  • | 3. DEFINITIVE THERAPY |
  • | - Radioactive Iodine Ablation (131-I): Treatment of choice for Graves' and TMNG in US; causes |
  • | permanent hypothyroidism within 3-6 months. Contraindicated in pregnancy and severe orbitopathy.|
  • | - Total Thyroidectomy: Indicated for large obstructive goiters, suspected malignancy, or severe |
  • | Graves' ophthalmopathy. Pre-op prep: Euthyroid with MMI + Lugol's iodine to reduce vascularity.|
  • +---------------------------------------------------------------------------------------------------+

Caution

Life-Threatening Thionamide Complications:

Agranulocytosis (Absolute Neutrophil Count < 500 / μ L <500/\mu\text{L} < 500/ μ L ): Occurs in 0.2–0.5% of patients on MMI or PTU, typically within the first 90 days. Presenting symptoms: acute high fever and severe sore throat / pharyngitis . The AGPCNP must educate the patient to immediately stop the medication and present for an emergent Complete Blood Count (CBC) with differential. Never treat empirically with oral antibiotics without a CBC.

Hepatotoxicity: PTU carries an FDA Black Box Warning for Fulminant Hepatic Failure (hepatocellular necrosis). MMI carries a risk of cholestatic jaundice (elevated alkaline phosphatase and bilirubin). Obtain baseline liver function tests before starting thionamides.

D. Thyroid Storm (Accelerated Thyrotoxic Crisis)

Clinical Presentation: Acute life-threatening crisis (mortality 10–30%) triggered by infection, surgery, trauma, or radioiodine therapy in an untreated thyrotoxic patient. Quantified using the Burch-Wartofsky Point Scale (evaluates thermoregulatory, CNS, cardiovascular, and gastrointestinal/hepatic dysfunction).

Hallmark Features: Severe hyperpyrexia ( 39 – 41 ∘ C [ 102 – 106 ∘ F ] 39\text{--}41^\circ\text{C} [102\text{--}106^\circ\text{F}] 39 – 4 1 ∘ C [ 102 – 10 6 ∘ F ] ), marked tachycardia ( > 140 bpm >140\text{ bpm} > 140 bpm ), atrial fibrillation, congestive heart failure, extreme agitation, delirium, psychosis, nausea, vomiting, diarrhea, jaundice, and shock.

The Four-Step Sequential Medical Protocol:

Step 1: Beta-Blockade: IV Propranolol (1–2 mg IV q15min or 60–80 mg PO q4h) to control sympathetic overdrive and inhibit peripheral deiodination.

Step 2: Antithyroid Synthesis Blockade: PTU 500–1,000 mg loading dose PO/NG, then 200–250 mg q4h (preferred over MMI due to dual action).

Step 3: Thyroid Hormone Release Blockade (Inorganic Iodine): Saturated Solution of Potassium Iodide ( SSKI 5 drops PO q6h) or Lugol's solution (10 drops PO q8h). CRITICAL TIMING RULE: Inorganic iodine must be administered at least 1 hour AFTER the thionamide dose . Giving iodine before thionamide provides substrate for new hormone synthesis ( Wolff-Chaikoff vs. Jod-Basedow catastrophe ).

Step 4: Corticosteroid Therapy: IV Hydrocortisone (100 mg IV q8h) or Dexamethasone (2 mg IV q6h) to treat relative adrenal insufficiency and further block peripheral T4 to T3 conversion.

4. The Thyroiditis Spectrum: Painful vs. Painless Subtypes +---------------------------------------------------------------------------------------------------+

  • | THE THYROIDITIS SPECTRUM DECISION MATRIX |
  • | |
  • | SUBTYPE ETIOLOGY & MECHANISM PAIN STATUS LAB & RAIU PROFILE TREATMENT |
  • | --------------------------------------------------------------------------------------------- |
  • | Subacute Granulomatous Post-viral (Coxsackie, EXQUISITELY ESR/CRP markedly NSAIDs or |
  • | (De Quervain / Giant) mumps, adenovirus). PAINFUL / elevated (>50-100); Prednisone |
  • | Granulomatous rupture. TENDER GLAND RAIU < 5%; Triphasic | (No MMI) |
  • | Subacute Lymphocytic Autoimmune variant. PAINLESS Anti-TPO positive Beta-blocker|
  • | (Silent Thyroiditis) Lymphocytic infiltrate. (Non-tender) in 50%; RAIU < 5%; for hyper- |
  • | Self-limiting thyroid phase|
  • | Postpartum Autoimmune within 12 mo PAINLESS Anti-TPO positive Beta-blocker|
  • | Thyroiditis of delivery; rebound. (Non-tender) in 80%; RAIU < 5%; (Avoid MMI/|
  • | Triphasic course PTU / RAI) |
  • | Acute Suppurative Bacterial infection SEVERELY Marked leukocytosis; IV Ceftriaxone|
  • | Thyroiditis (Staph, Strep, piriform). PAINFUL + ERY- Normal thyroid fxn; + Vanco + |
  • | THEMA/WARMTH Abscess on ultrasound| Drainage |
  • | Riedel's Thyroiditis IgG4 systemic fibrosing PAINLESS Normal/hypothyroid; Surgical |
  • | disorder; woody fibrosis. "STONE-HARD" Cold scan; extensive decompression|
  • | FIXED GLAND local invasion + Tamoxifen|
  • +---------------------------------------------------------------------------------------------------+

The Triphasic Clinical Trajectory of Destructive Thyroiditis:

In subacute, silent, and postpartum thyroiditis, follicular cell destruction triggers a predictable 3-phase course:

Hyperthyroid Phase (Weeks 1–6): Pre-formed thyroid hormone leaks into the circulation → \rightarrow → low TSH, high Free T4/T3, RAIU is suppressed (<5%) . Treat solely with beta-blockers (propranolol) for symptoms. Thionamides (MMI/PTU) and radioiodine are completely ineffective and contraindicated because there is no new hormone synthesis!

Hypothyroid Phase (Weeks 6–16): Thyroid hormone stores are depleted while follicular cells recover → \rightarrow → elevated TSH, low Free T4. If symptomatic, initiate temporary, low-dose levothyroxine.

Recovery / Euthyroid Phase (Months 4–12): 90–95% of patients recover full baseline thyroid function; ~5% develop permanent hypothyroidism requiring lifelong levothyroxine.

5. Thyroid Nodules & Thyroid Cancer: Diagnostic Workup & TI-RADS Stratification

Thyroid nodules are identified in up to 50–60% of healthy adult women on high-resolution neck ultrasonography. The primary clinical objective is excluding the 5–10% that harbor thyroid carcinoma. +---------------------------------------------------------------------------------------------------+

  • | EVALUATION ALGORITHM FOR THE PALPABLE THYROID NODULE |
  • | |
  • | [PALPABLE NODULE OR INCIDENTAL FINDING ON CT/US] |
  • | | |
  • | v |
  • | [ORDER SERUM TSH LEVEL] |
  • | | |
  • | +---------------------------+---------------------------+ |
  • | | | |
  • | v v |
  • | [SUPPRESSED TSH (<0.4)] [NORMAL OR ELEVATED TSH] |
  • | | | |
  • | v v |
  • | [RADIONUCLIDE SCAN (I-123)] [HIGH-RESOLUTION NECK US] |
  • | | | |
  • | +-------------+-------------+ v |
  • | | | [STRATIFY VIA ACR TI-RADS] |
  • | v v | |
  • | ["HOT" (FUNCTIONING)] ["COLD" (NON-FUNCTIONING)] v |
  • | - Autonomous adenoma - Malignancy risk ~10-15% [FINE NEEDLE ASPIRATION (FNA)]|
  • | - Malignancy < 1% - Proceed to NECK US & Based on TI-RADS score and |
  • | - Treat hyperthyroidism FNA based on TI-RADS criteria size thresholds (>=1.0-1.5 cm)|
  • +---------------------------------------------------------------------------------------------------+

High-Risk Sonographic Features (ACR TI-RADS):

Solid composition (vs. cystic or spongiform).

Hypoechogenicity (darker than adjacent strap muscles).

Taller-than-wide morphology (anteroposterior diameter > transverse diameter on transverse view).

Irregular, lobulated, or infiltrative margins (or extrathyroidal extension).

Punctate echogenic foci / Microcalcifications (represent psammoma bodies).

Thyroid Malignancy Classification Matrix

Carcinoma Subtype Prevalence Histopathology & Genetic Drivers Clinical Behavior & Metastatic Route Prognosis & Management

Papillary Thyroid Carcinoma (PTC) 80 - 85% • Psammoma bodies ; • "Orphan Annie eyes" (ground-glass nuclei); • Nuclear grooves; • BRAF V600E , RET/PTC Indolent; spreads primarily via cervical lymphatics ; history of neck radiation exposure. Excellent (10-yr survival >95%) ; Lobectomy or total thyroidectomy ± \pm ± 131-I ablation ± \pm ± TSH suppression.

Follicular Thyroid Carcinoma (FTC) 10 - 15% • Capsular and/or vascular invasion; • RAS mutations, PAX8-PPARG ; • (FNA cannot distinguish adenoma vs cancer) Spreads hematogenously to bone and lungs; common in iodine-deficient areas. Good (10-yr survival ~85%) ; Total thyroidectomy + 131-I ablation; monitor serum Thyroglobulin (Tg) as tumor marker.

Medullary Thyroid Carcinoma (MTC) 4 - 5% • Originates from parafollicular C-cells ; • Amyloid stroma (calcitonin deposits); • RET proto-oncogene (MEN 2A/2B) Calcitonin and CEA secreting; spreads to lymph nodes, liver, bone. Moderate (10-yr survival ~75%) ; Total thyroidectomy + central neck dissection. Screen for Pheochromocytoma before surgery!

Anaplastic Thyroid Carcinoma < 2% • Highly undifferentiated pleomorphic spindle cells; • TP53 mutations Extremely aggressive; rapid neck mass growth with hoarseness (RLN palsy), stridor, dysphagia . Dismal (Median survival 3-6 mo) ; Palliative airway management, radiation, chemotherapy (rarely operable).

6. Board-Yield Summary & Clinical Pearls +---------------------------------------------------------------------------------------------------+

  • | ANCC AGPCNP CLINICAL EXAM PEARLS |
  • | |
  • | - Start Low, Go Slow in Geriatrics / CAD: Never initiate full-dose levothyroxine in an older |
  • | adult or patient with CAD (start 12.5-25 mcg/day). Rapid titration induces fatal MI / AFib. |
  • | |
  • | - Thionamide S.O.S.: Sore throat and fever in a patient on Methimazole or PTU = AGRANULOCYTOSIS |
  • | until proven otherwise! Stop drug immediately and draw STAT CBC with differential. |
  • | |
  • | - Pregnancy Thionamide Rule: 1st Trimester = PTU (prevents MMI aplasia cutis); 2nd and 3rd |
  • | Trimesters = Methimazole (prevents PTU fulminant hepatic necrosis). |
  • | |
  • | - Thyroiditis Rule: Subacute painful thyroiditis = High ESR + Low RAIU (<5%). Do NOT prescribe |
  • | Methimazole or PTU! Treat hyperthyroid symptoms with beta-blockers and pain with NSAIDs/steroids.|
  • | |
  • | - Thyroid Nodule Workup First Step: Check Serum TSH. Low TSH -> Radionuclide scan; Normal/High |
  • | TSH -> High-resolution Neck Ultrasound -> FNA based on TI-RADS. |
  • +---------------------------------------------------------------------------------------------------+